Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 2

New treatment options in allergic rhinitis: patient considerations and the role of ciclesonide

Authors Braido F, Lagasio C, Piroddi IMG, Baiardini I, Canonica GW

Published 11 April 2008 Volume 2008:4(2) Pages 353—361

DOI https://doi.org/10.2147/TCRM.S1266

F Braido, C Lagasio, IMG Piroddi, I Baiardini, GW Canonica

Allergy and Respiratory Diseases Department, University of Genoa, Italy

Abstract: Allergic rhinitis (AR) is a chronic inflammatory respiratory disease affecting 5%–50% of the worldwide population and its prevalence is increasing (Herman 2007). In addition, AR is associated with asthma and other co-morbidities such as conjunctivitis and sinusitis. The main symptoms are nasal congestion, rhinorrea, sneezing, itching, and post-nasal drainage induced after allergen exposure by an IgE-mediated inflammation of the membranes lining the nose. AR is not a life-threatening disease, but it has been shown to have a significant impact on quality of life. The Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines propose a classification of AR in intermittent and persistent, each graded as mild or moderate-severe, and provide a stepwise approach to the treatment. Inhaled steroids and antihistamine are the main tools in AR therapy but more safe and effective drugs are, however, needed. Inhaled steroid ciclesonide appears to be safe and effective.

Keywords: ciclesonide, allergic rhinitis, asthma, quality of life

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]